Symbol Lookup from Yahoo Finance

Trending Tickers

Symbol	Name	Last Price	Change	Change %
RIVN	Rivian Automotive, Inc.	11.60	+1.36	+13.28%
ZENA	ZenaTech, Inc.	6.42	+4.63	+258.66%
BBY	Best Buy Co., Inc.	93.03	+3.49	+3.90%
LLY	Eli Lilly and Company	755.00	+6.99	+0.93%
KSS	Kohl's Corporation	18.34	+1.31	+7.69%
ZM	Zoom Video Communications, Inc.	89.03	+3.15	+3.67%
PSTX	Poseida Therapeutics, Inc.	2.8600	+0.1300	+4.76%
ANF	Abercrombie & Fitch Company	154.50	+2.51	+1.65%
DKS	Dick's Sporting Goods Inc	215.23	+5.07	+2.41%
BTC-USD	Bitcoin USD	92,288.47	-5,562.68	-5.68%
AMGN	Amgen Inc.	294.00	-0.53	-0.18%
ADI	Analog Devices, Inc.	223.58	+8.99	+4.19%
IDAI	T Stamp Inc.	0.1800	+0.0045	+2.56%
MDAI	Spectral AI, Inc.	1.3100	+0.1200	+10.08%
HIMS	Hims & Hers Health, Inc.	31.35	+6.02	+23.77%
SJM	The J.M. Smucker Company	113.62	+0.32	+0.28%
VKTX	Viking Therapeutics, Inc.	51.99	-0.60	-1.14%
NVO	Novo Nordisk A/S	104.56	-0.50	-0.48%
SMTC	Semtech Corporation	53.44	+2.55	+5.01%
ARWR	Arrowhead Pharmaceuticals, Inc.	18.79	+0.25	+1.35%
CTXR	Citius Pharmaceuticals, Inc.	3.3375	+3.2037	+2,394.39%
VSEE	VSee Health, Inc.	1.7200	+0.2400	+16.22%
INTC	Intel Corporation	24.87	+0.37	+1.51%
CADUSD=X	USD/CAD	1.4099	+0.0114	+0.81%
SAVA	Cassava Sciences, Inc.	4.2950	-22.1850	-83.78%

Related News

Best Buy broadly misses earnings estimates as consumers pull back on appliances, electronics

Best Buy could get a boost as consumers flock to new, AI-enabled products.

Yahoo Finance 55 minutes ago

BBY

^GSPC
Kohl's announces CEO shakeup ahead of Q3 earnings

Kohl's (KSS) announced that CEO Tom Kingsbury will be stepping down from the role effective January 15, 2025. Michaels Companies CEO Ashley Buchanan has been named his replacement. In the release, Kohl's says Kingsbury will serve in an advisory role and stay on the company's board through his retirement in May 2025. Yahoo Finance Senior Reporter Brooke DiPalma reports on the breaking details. To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend here. This post was written by Stephanie Mikulich.

Yahoo Finance Video 15 hours ago

KSS
Hims & Hers surges: Analysts say it's well-positioned under Trump

Hims & Hers Health (HIMS) has soared after Hunterbrook Media says that the company could benefit from President-elect Donald Trump's Food and Drug Administration (FDA) nomination Marty Makary. Julie Hyman and Josh Lipton break down what investors need to know on Market Domination. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Naomi Buchanan.

Yahoo Finance Video 16 hours ago

HIMS
MicroStrategy makes additional $5.4B bitcoin purchase

MicroStrategy (MSTR) stock is experiencing downward pressure following the company's latest bitcoin purchase of 55,000 coins, worth approximately $5.4 billion. The investment comes amid a challenging trading session for bitcoin (BTC-USD), which is slipping on Monday. Led by CEO Michael Saylor, MicroStrategy is known for its aggressive bitcoin acquisition strategy, positioning the company as one of the largest corporate holders of the cryptocurrency. Market Domination Hosts Julie Hyman and Josh Lipton break down Wall Street outlooks on the name. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Angel Smith

Yahoo Finance Video 17 hours ago

BTC-USD

MSTR
Bitcoin rally stall creates entry point for FOMO investors

Bitcoin (BTC-USD) pulls back from its election-fueled rally that was originally pushing it closer and closer to $100,000. Digital Assets Council of Financial Professionals president Don Friedman joins Seana Smith and Madison Mills on Catalysts to discuss the move and what it is signaling about the cryptocurrency market's reception to a second Trump administration. "I really don't think it's anything to worry about," Friedman says, explaining, "Think about several years ago, we had this discussion about $20,000. It went lower then we had this discussion earlier this year at $73,000. And now we're having this discussion again at $100,000. So we look at this as a phenomenal opportunity to dollar-cost average your way in." Dollar-cost averaging is investing a set amount in regular intervals to minimize the impact of price fluctuations on average cost per share. "As you can imagine, people have FOMO, [the] fear of missing out, and that makes people nervous," Friedman tells Yahoo Finance. "When you dollar-cost average, you're robotic. It's [mechanical]. You're buying it on a regular basis. And that way, you're in a good spot for the long term." Metafide CEO Frank Speiser told Yahoo Finance last week that he is forecasting bitcoin to hit as high as $500,000 by 2027. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. This post was written by Naomi Buchanan.

Yahoo Finance Video 21 hours ago

BTC-USD
US to reduce Intel's CHIPS grant to below $8 billion: NYT

The US is reducing its CHIPS & Science Act grant allotted to Intel (INTC) to below $8 billion, down from the originally proposed $8.5 billion, as officials account for the semiconductor giant's other $3 billion-plus grant for making chips for the Pentagon. The Morning Brief's Seana Smith and Brad Smith break down the New York Times report while Intel's stock moves to the upside this morning. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Luke Carberry Mogan.

Yahoo Finance Video 22 hours ago

INTC
These Stocks Are Moving the Most Today: Rivian, Ford, Amgen, Zoom, Semtech, Analog Devices, Dick’s, Kohl’s, and More

Rivian receives a loan of up to $6.6 billion from the U.S. government to boost electric-vehicle production, while shares of Ford and General Motors fall after President-elect Donald Trump announces his tariff plans.

Barrons.com 6 minutes ago

CRWD

RIVN
Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau

On Tuesday, Amgen Inc (NASDAQ:AMGN) stock fell during the premarket session after the company released long-anticipated data from the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133) in obese patients. The company said that MariTide demonstrated up to ~20% average weight loss at one year (52 weeks) without a weight loss plateau, indicating the potential for further weight loss beyond 52 weeks. Amgen’s stock dropped as the results seemed to fall short of Wall Street’s high ex

Benzinga 8 minutes ago

AMGN
Analog Devices beats Q4 targets on chip demand recovery from auto industry

Chipmaker Analog Devices topped analysts' estimates for fourth-quarter revenue and profit on Tuesday, helped by strong demand for its semiconductors used in consumer electronics and a recovery in orders from the auto industry. Shares of the Wilmington, Massachusetts-based company rose 7% in premarket trading. Demand for consumer electronics has recovered from a post-pandemic lull, while trends in the auto segment are also improving.

Reuters 11 minutes ago

ADI
Amgen Stock Dives Despite Positive Weight-Loss Drug Data. What to Know.

Amgen stock was dropping in premarket trading, despite positive data from a Phase 2 study for its experimental weight-loss drug, MariTide. The pharmaceutical company said in a statement that after 52 weeks, there was an average 20% weight loss “in people living with obesity or overweight without Type 2 diabetes.” It said the numbers didn’t plateau, which indicated MariTide’s potential for further weight loss beyond 52 weeks.

Barrons.com 13 minutes ago

AMGN

LLY
Kohl's Stock Crashes 17% as Weak Performance and CEO Shake-Up Rock Investor Confidence

Disappointing Q3 results, slashed forecasts, and a leadership overhaul spark fears for Kohl's future

GuruFocus.com 15 minutes ago

KSS
Kohl's Q3 Misses The Mark: Weak Sales And CEO Shake-Up Send Shares Down

Kohl’s Corp (NYSE:KSS) shares are trading lower after the company reported third-quarter earnings. The company reported a net sales decline of 8.8% year-over-year (Y/Y) to $3.507 billion, missing the consensus of $3.638 billion. Comparable sales for the quarter decreased 9.3%. Total revenue stood at $3.710 billion. Gross margin for the quarter expanded by 20 basis points to 39.1%. Operating income for the quarter was $98 million versus $157 million last year. The operating margin contracted 120

Benzinga 16 minutes ago

KSS
Best Buy reports another quarterly sales decline as shoppers pull back spending on gadgets

Best Buy, the nation’s largest consumer electronics chain, on Tuesday reported another quarterly drop in sales as Americans continued to tighten their purse strings on appliances and gadgets to focus on essentials. The Richfield, Minnesota-based retailer lowered its annual sales and profit outlook, sending its shares down 2.6% in premarket trading. The company reported earnings of $273 million, or $1.26 per share, for the quarter ended Nov. 2.

Associated Press Finance 17 minutes ago

BBY
Kohl’s 3Q Sales Decline, New 2024 Outlook Suggests Tough Holiday Period

Kohl’s saw sales decline in the latest quarter while its revised outlook for the year suggested a challenging upcoming holiday period, creating a challenging setup for its next chief executive.

The Wall Street Journal 24 minutes ago

KSS
Arrowhead Pharma, Sarepta Therapeutics Sign Licensing, Partnership Deal for Clinical, Preclinical Programs

Arrowhead Pharmaceuticals (ARWR) and Sarepta Therapeutics (SRPT) have struck a global licensing and partnership deal for clinical and preclinical programs in genetic diseases of the muscle, central nervous system, and lungs, the companies said Tuesday.

PREMIUM
MT Newswires 30 minutes ago

SRPT

ARWR
Zoom Rebrands Itself Remove the Word Video from Its Name

Zoom Rebrands as Zoom Communications Inc, Embracing AI-Centric Products for Corporate Communications

GuruFocus.com 31 minutes ago

ZM
Dow Jones Futures Fall On Trump Tariff Threat; Nvidia Stock Hangs At Key Level

Dow Jones futures dropped Tuesday on President-elect Donald Trump's tariff threat on China, Canada and Mexico. Nvidia is at a key level.

Investor's Business Daily 33 minutes ago

DKS

BBY
Amgen falls after obesity study results

Investing.com -- Shares of Amgen (NASDAQ: NASDAQ:AMGN) dropped 7.4% in premarket trading Tuesday following the release of Phase 2 trial results for its obesity drug candidate, MariTide (formerly AMG 133).

Investing.com 33 minutes ago

AMGN
Best Buy Says Q3 Sales 'Little Softer Than Expected' On Lower Demand For Appliances And Gaming, Trims Annual Forecast

On Tuesday, Best Buy Co., Inc (NYSE:BBY) reported fiscal 2025 third-quarter adjusted EPS of $1.26, missing the consensus of $1.29. Enterprise comparable sales fell 2.9%. Quarterly sales decreased to $9.45 billion from $9.76 billion a year ago, missing the analyst consensus of $9.63 billion. Domestic revenue of $8.70 billion decreased 3.3% compared to last year, primarily due to a comparable sales decline of 2.8%. From a merchandising perspective, the largest drivers of the comparable sales decli

Benzinga 34 minutes ago

BBY
Abercrombie's Record Quarter Stuns, But Wall Street Isn't Sold--What's Next

Blowout earnings, bold forecasts, and a new CFO--why Abercrombie & Fitch's stock stumbled despite big wins.

GuruFocus.com 37 minutes ago

ANF

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Trending Tickers

Related News

Best Buy broadly misses earnings estimates as consumers pull back on appliances, electronics

Kohl's announces CEO shakeup ahead of Q3 earnings

Hims & Hers surges: Analysts say it's well-positioned under Trump

MicroStrategy makes additional $5.4B bitcoin purchase

Bitcoin rally stall creates entry point for FOMO investors

US to reduce Intel's CHIPS grant to below $8 billion: NYT

These Stocks Are Moving the Most Today: Rivian, Ford, Amgen, Zoom, Semtech, Analog Devices, Dick’s, Kohl’s, and More

Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau

Analog Devices beats Q4 targets on chip demand recovery from auto industry

Amgen Stock Dives Despite Positive Weight-Loss Drug Data. What to Know.

Kohl's Stock Crashes 17% as Weak Performance and CEO Shake-Up Rock Investor Confidence

Kohl's Q3 Misses The Mark: Weak Sales And CEO Shake-Up Send Shares Down

Best Buy reports another quarterly sales decline as shoppers pull back spending on gadgets

Kohl’s 3Q Sales Decline, New 2024 Outlook Suggests Tough Holiday Period

Arrowhead Pharma, Sarepta Therapeutics Sign Licensing, Partnership Deal for Clinical, Preclinical Programs

Zoom Rebrands Itself Remove the Word Video from Its Name

Dow Jones Futures Fall On Trump Tariff Threat; Nvidia Stock Hangs At Key Level

Amgen falls after obesity study results

Best Buy Says Q3 Sales 'Little Softer Than Expected' On Lower Demand For Appliances And Gaming, Trims Annual Forecast

Abercrombie's Record Quarter Stuns, But Wall Street Isn't Sold--What's Next